SCHEMBL6393993

SCHEMBL6393993

O/N=C/c1cc2ccccc2[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.61
GRIN3B O60391 1/20 0.61
GRIN1 Q05586 1/20 0.61
GRIN2A Q12879 1/20 0.61
GRIN2B Q13224 1/20 0.61
GRIN2C Q14957 1/20 0.61
GRIN3A Q8TCU5 1/20 0.61
CYP2A6 P11509 1/20 0.58
AMY1A P0DUB6 1/20 0.57
MAPT P10636 2/20 0.47
IDO1 P14902 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6393996 1.00 GRIN2D (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19420144 0.84 GRIN2D (0.70) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7096273 0.81 GRIN2D (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL14337209 0.81 CYP2A6 (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL14337328 0.78 CYP2A6 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1177659 0.78 CYP2A6 (0.64) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2458425 0.77 CYP2A6 (0.69) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2458423 0.77 CYP2A6 (0.69) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL28181946 0.77 CYP2A6 (0.69) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27145202 0.77 CYP19A1 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed
US-20050267303-A1 Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals ZENTARIS AG 2005-12-01 US disclosed
US-20040039197-A1 Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals WATERWORKS, INC. 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267303-A1 Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals IDO1, IDO2, INMT GRIN2D 2029/4885GRIN3B 2808/4885GRIN1 1919/4885
US-20040039197-A1 Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals IDO1, IDO2, INMT GRIN2D 1735/4885GRIN3B 2536/4885GRIN1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.